|
1
|
Dolecek TA, Propp JM, Stroup NE and
Kruchko C: CBTRUS statistical report: Primary brain and central
nervous system tumors diagnosed in the United States in 2005–2009.
Neuro Oncol. 14:(Suppl 5). v1–v49. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stupp R and Roila F: ESMO Guidelines
Working Group: Malignant glioma: ESMO clinical recommendations for
diagnosis, treatment and follow-up. Ann Oncol. 20:(Suppl 4).
S126–S128. 2009. View Article : Google Scholar
|
|
4
|
Nagaraja AS, Armaiz-Pena GN, Lutgendorf SK
and Sood AK: Why stress is BAD for cancer patients. J Clin Invest.
123:558–560. 2013.PubMed/NCBI
|
|
5
|
Thaker PH, Han LY, Kamat AA, Arevalo JM,
Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori
M, et al: Chronic stress promotes tumor growth and angiogenesis in
a mouse model of ovarian carcinoma. Nat Med. 12:939–944. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hassan S, Karpova Y, Baiz D, Yancey D,
Pullikuth A, Flores A, Register T, Cline JM, D'Agostino R Jr,
Danial N, et al: Behavioral stress accelerates prostate cancer
development in mice. J Clin Invest. 123:874–886. 2013.PubMed/NCBI
|
|
7
|
Timmermans W, Xiong H, Hoogenraad CC and
Krugers HJ: Stress and excitatory synapses: From health to disease.
Neuroscience. 248:626–636. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
de Kloet ER, Joëls M and Holsboer F:
Stress and the brain: From adaptation to disease. Nat Rev Neurosci.
6:463–475. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fitzgerald PJ: Is norepinephrine an
etiological factor in some types of cancer? Int J Cancer.
124:257–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Woo AY and Xiao RP: β-adrenergic receptor
subtype signaling in heart: From bench to bedside. Acta Pharmacol
Sin. 33:335–341. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schuller HM and Al-Wadei HA:
Neurotransmitter receptors as central regulators of pancreatic
cancer. Future Oncol. 6:221–228. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cohen S, Janicki-Deverts D and Miller GE:
Psychological stress and disease. JAMA. 298:1685–1687. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schuller HM: Beta-adrenergic signaling, a
novel target for cancer therapy? Oncotarget. 1:466–469. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Braadland PR, Ramberg H, Grytli HH and
Taskén KA: β-adrenergic receptor signaling in prostate cancer.
Front Oncol. 4:3752015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Al-Wadei HA, Al-Wadei MH and Schuller HM:
Prevention of pancreatic cancer by the beta-blocker propranolol.
Anticancer Drugs. 20:477–482. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Askari MD, Tsao MS and Schuller HM: The
tobacco-specific carcinogen,
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates
proliferation of immortalized human pancreatic duct epithelia
through beta-adrenergic transactivation of EGF receptors. J Cancer
Res Clin Oncol. 131:639–648. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Weddle DL, Tithoff P, Williams M and
Schuller HM: Beta-adrenergic growth regulation of human cancer cell
lines derived from pancreatic ductal carcinomas. Carcinogenesis.
22:473–479. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Toll L, Jimenez L, Waleh N, Jozwiak K, Woo
AY, Xiao RP, Bernier M and Wainer IW: {Beta}2-adrenergic receptor
agonists inhibit the proliferation of 1321N1 astrocytoma cells. J
Pharmacol Exp Ther. 336:524–532. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu P, He J, Liu S, Wang M, Pan B and Zhang
W: β2-adrenergic receptor activation promotes the proliferation of
A549 lung cancer cells via the ERK1/2/CREB pathway. Oncol Rep.
36:1757–1763. 2016.PubMed/NCBI
|
|
21
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dong W, Li H, Zhang Y, Yang H, Guo M, Li L
and Liu T: Matrix metalloproteinase 2 promotes cell growth and
invasion in colorectal cancer. Acta Biochim Biophys Sin (Shanghai).
43:840–848. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Annabi B, Lachambre MP, Plouffe K,
Moumdjian R and Béliveau R: Propranolol adrenergic blockade
inhibits human brain endothelial cells tubulogenesis and matrix
metalloproteinase-9 secretion. Pharmacol Res. 60:438–445. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sardi I, Giunti L, Bresci C, Buccoliero
AM, Degl'innocenti D, Cardellicchio S, Baroni G, Castiglione F, Ros
MD, Fiorini P, et al: Expression of β-adrenergic receptors in
pediatric malignant brain tumors. Oncol Lett. 5:221–225.
2013.PubMed/NCBI
|
|
26
|
Prenner L, Sieben A, Zeller K, Weiser D
and Häberlein H: Reduction of high-affinity beta2-adrenergic
receptor binding by hyperforin and hyperoside on rat C6
glioblastoma cells measured by fluorescence correlation
spectroscopy. Biochemistry. 46:5106–5113. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wakshull E, Hertel C, O'Keefe EJ and
Perkins JP: Cellular redistribution of beta-adrenergic receptors in
a human astrocytoma cell line: A comparison with the epidermal
growth factor receptor in murine fibroblasts. J Cell Biochem.
29:127–141. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Paul RK, Ramamoorthy A, Scheers J, Wersto
RP, Toll L, Jimenez L, Bernier M and Wainer IW: Cannabinoid
receptor activation correlates with the proapoptotic action of the
β2-adrenergic agonist (R,R')-4-methoxy-1-naphthylfenoterol in HepG2
hepatocarcinoma cells. J Pharmacol Exp Ther. 343:157–166. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Evans BA, Sato M, Sarwar M, Hutchinson DS
and Summers RJ: Ligand-directed signalling at beta-adrenoceptors.
Br J Pharmacol. 159:1022–1038. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yuan A, Li Z, Li X, Yi S, Wang S, Cai Y
and Cao H: The mitogenic effectors of isoproterenol in human
hepatocellular carcinoma cells. Oncol Rep. 23:151–157.
2010.PubMed/NCBI
|
|
31
|
Pham H, Chen M, Takahashi H, King J, Reber
HA, Hines OJ, Pandol S and Eibl G: Apigenin inhibits NNK-induced
focal adhesion kinase activation in pancreatic cancer cells.
Pancreas. 41:1306–1315. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang P, He X, Tan J, Zhou X and Zou L:
β-arrestin2 mediates β-2 adrenergic receptor signaling inducing
prostate cancer cell progression. Oncol Rep. 26:1471–1477.
2011.PubMed/NCBI
|
|
33
|
Shin VY, Wu WK, Chu KM, Koo MW, Wong HP,
Lam EK, Tai EK and Cho CH: Functional role of beta-adrenergic
receptors in the mitogenic action of nicotine on gastric cancer
cells. Toxicol Sci. 96:21–29. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Coelho M, Moz M, Correia G, Teixeira A,
Medeiros R and Ribeiro L: Antiproliferative effects of β-blockers
on human colorectal cancer cells. Oncol Rep. 33:2513–2520.
2015.PubMed/NCBI
|
|
35
|
Slotkin TA, Zhang J, Dancel R, Garcia SJ,
Willis C and Seidler FJ: Beta-adrenoceptor signaling and its
control of cell replication in MDA-MB-231 human breast cancer
cells. Breast Cancer Res Treat. 60:153–166. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Carie AE and Sebti SM: A chemical biology
approach identifies a beta-2 adrenergic receptor agonist that
causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2
pathway. Oncogene. 26:3777–3788. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schuller HM, Al-Wadei HA and Majidi M:
GABA B receptor is a novel drug target for pancreatic cancer.
Cancer. 112:767–778. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cottingham C, Lu R, Jiao K and Wang Q:
Cross-talk from β-adrenergic receptors modulates α2A-adrenergic
receptor endocytosis in sympathetic neurons via protein kinase A
and spinophilin. J Biol Chem. 288:29193–29205. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hanke S, Nürnberg B, Groll DH and Liebmann
C: Cross talk between beta-adrenergic and bradykinin B(2) receptors
results in cooperative regulation of cyclic AMP accumulation and
mitogen-activated protein kinase activity. Mol Cell Biol.
21:8452–8460. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wrzal PK, Goupil E, Laporte SA, Hébert TE
and Zingg HH: Functional interactions between the oxytocin receptor
and the β2-adrenergic receptor: Implications for ERK1/2 activation
in human myometrial cells. Cell Signal. 24:333–341. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Moreno-Smith M, Lutgendorf SK and Sood AK:
Impact of stress on cancer metastasis. Future Oncol. 6:1863–1881.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xiao LJ, Lin P, Lin F, Liu X, Qin W, Zou
HF, Guo L, Liu W, Wang SJ and Yu XG: ADAM17 targets MMP-2 and MMP-9
via EGFR-MEK-ERK pathway activation to promote prostate cancer cell
invasion. Int J Oncol. 40:1714–1724. 2012.PubMed/NCBI
|
